NASDAQ$THRD
Third Harmonic Bio Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced second quarter 2024 financial results and provided business update.
Third Harmonic Bio reported a net loss of $10.7 million for the second quarter of 2024, with cash and cash equivalents totaling $255.3 million as of June 30, 2024. The company believes its current cash will fund operations through at least 2026. Clinical results for the THB335 Phase 1 SAD/MAD clinical trial are expected in 1Q'25.
- THB335 Phase 1 SAD/MAD clinical trial progressing with clinical results expected in 1Q’25.
- Cash and cash equivalents totaled $255.3 million as of June 30, 2024.
- R&D expenses increased to $8.4 million for the three months ended June 30, 2024.
- Net loss for the three months ended June 30, 2024, increased to $10.7 million.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Forward guidance
The company anticipates clinical trial progress and expects existing cash and cash equivalents to fund operations through at least 2026.
Tailwinds
- Expected timing for clinical trials
- Progress of the clinical trials
- Availability of clinical data from such trials
- Planned clinical and development activities and timelines
- Sufficiency of Third Harmonic Bio’s cash and cash equivalents to fund its operating expenses and capital expenditure requirements through at least 2026
Headwinds
- Risks and uncertainties related to Third Harmonic Bio’s cash forecasts
- Ability to advance its product candidates
- The receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates
- Changes to laws or regulations
- Market conditions, geopolitical events, and further impacts of pandemics or health epidemics
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q2 2024
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro